Compare Stocks: PCSA, TVRD, BFRI, and KPTI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$0.84 -5.7%	$1.28	$0.55 ▼ $1.66	$12.65M	0.86	414,729 shs	187,761 shs
KPTI Karyopharm Therapeutics	$0.34 -20.7%	$1.60	$0.34 ▼ $10.99	$7.87M	1.04	1.05 million shs	1.15 million shs
PCSA Heatwurx	$1.69 -4.8%	$2.00	$1.04 ▼ $11.00	$4.73M	1.2	131,965 shs	11,777 shs
TVRD Tvardi Therapeutics	$1.01 -3.1%	$1.62	$0.93 ▼ $7.23	$13.41M	0.38	808,634 shs	42,919 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	-3.56%	-4.27%	-42.44%	-18.15%	-5.29%
KPTI Karyopharm Therapeutics	-15.38%	-34.24%	-73.45%	-95.52%	-92.40%
PCSA Heatwurx	-6.84%	+18.55%	-14.90%	-25.94%	-83.95%
TVRD Tvardi Therapeutics	-1.89%	-3.70%	-44.39%	-64.51%	-84.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$0.84 -5.7%	$1.28	$0.55 ▼ $1.66	$12.65M	0.86	414,729 shs	187,761 shs
KPTI Karyopharm Therapeutics	$0.34 -20.7%	$1.60	$0.34 ▼ $10.99	$7.87M	1.04	1.05 million shs	1.15 million shs
PCSA Heatwurx	$1.69 -4.8%	$2.00	$1.04 ▼ $11.00	$4.73M	1.2	131,965 shs	11,777 shs
TVRD Tvardi Therapeutics	$1.01 -3.1%	$1.62	$0.93 ▼ $7.23	$13.41M	0.38	808,634 shs	42,919 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	-3.56%	-4.27%	-42.44%	-18.15%	-5.29%
KPTI Karyopharm Therapeutics	-15.38%	-34.24%	-73.45%	-95.52%	-92.40%
PCSA Heatwurx	-6.84%	+18.55%	-14.90%	-25.94%	-83.95%
TVRD Tvardi Therapeutics	-1.89%	-3.70%	-44.39%	-64.51%	-84.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRI Biofrontera	2.00	Hold	N/A	N/A
KPTI Karyopharm Therapeutics	2.57	Moderate Buy	$11.50	3,292.33% Upside
PCSA Heatwurx	1.00	Sell	N/A	N/A
TVRD Tvardi Therapeutics	2.86	Moderate Buy	$9.40	832.54% Upside

Current Analyst Ratings Breakdown

Latest PCSA, TVRD, BFRI, and KPTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/13/2026	BFRI Biofrontera	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/2/2026	TVRD Tvardi Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/24/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/10/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/8/2026	TVRD Tvardi Therapeutics	Lucid Cap Mkts Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
8/27/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/3/2026	BFRI Biofrontera	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
7/31/2026	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Negative
7/31/2026	KPTI Karyopharm Therapeutics	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$7.00
7/31/2026	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Neutral	$3.00

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRI Biofrontera	$41.71M	0.30	N/A	N/A	$0.90 per share	0.93
KPTI Karyopharm Therapeutics	$146.07M	0.05	N/A	N/A	($16.00) per share	-0.02
PCSA Heatwurx	N/A	N/A	N/A	N/A	$2.46 per share	N/A
TVRD Tvardi Therapeutics	$7.14M	1.88	N/A	N/A	$2.23 per share	0.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRI Biofrontera	-$10.54M	-$0.45	N/A	N/A	N/A	-13.78%	-145.81%	-31.30%	11/11/2026 (Estimated)
KPTI Karyopharm Therapeutics	-$196.04M	-$13.09	N/A	N/A	N/A	-153.28%	N/A	-145.18%	11/2/2026 (Estimated)
PCSA Heatwurx	-$13.56M	-$4.23	N/A	N/A	N/A	N/A	-394.25%	-244.46%	10/29/2026 (Estimated)
TVRD Tvardi Therapeutics	-$18.21M	-$2.79	N/A	N/A	N/A	N/A	-145.40%	-91.11%	N/A

Latest PCSA, TVRD, BFRI, and KPTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	BFRI Biofrontera	-$0.22	N/A	N/A	N/A	$8.25 million	N/A
11/2/2026	Q3 2026	KPTI Karyopharm Therapeutics	-$1.16	N/A	N/A	N/A	$33.54 million	N/A
10/29/2026	Q3 2026	PCSA Heatwurx	-$1.00	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	PCSA Heatwurx	-$1.00	-$1.19	-$0.19	-$1.19	N/A	N/A
8/14/2026	Q2 2026	TVRD Tvardi Therapeutics	-$0.65	-$0.69	-$0.04	-$0.69	N/A	N/A
8/13/2026	Q2 2026	BFRI Biofrontera	-$0.1050	-$0.05	+$0.0550	-$0.05	$9.50 million	$12.00 million
8/13/2026	Q2 2026	KPTI Karyopharm Therapeutics	-$1.37	-$2.32	-$0.95	-$2.32	$32.19 million	$33.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
PCSA Heatwurx	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRI Biofrontera	0.78	1.18	1.08
KPTI Karyopharm Therapeutics	N/A	0.79	0.76
PCSA Heatwurx	N/A	0.87	0.87
TVRD Tvardi Therapeutics	N/A	1.87	1.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFRI Biofrontera	10.08%
KPTI Karyopharm Therapeutics	66.44%
PCSA Heatwurx	91.93%
TVRD Tvardi Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
BFRI Biofrontera	8.10%
KPTI Karyopharm Therapeutics	1.68%
PCSA Heatwurx	3.50%
TVRD Tvardi Therapeutics	7.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRI Biofrontera	94	14.85 million	13.65 million	No Data
KPTI Karyopharm Therapeutics	228	22.68 million	22.30 million	Optionable
PCSA Heatwurx	12	2.80 million	2.67 million	Not Optionable
TVRD Tvardi Therapeutics	80	13.34 million	12.35 million	N/A

PCSA, TVRD, BFRI, and KPTI Headlines

Recent News About These Companies

Tvardi Therapeutics to Participate in Chardan's 10th Annual Healthcare Conference

October 14 at 8:00 AM | globenewswire.com

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Stock Has Consensus Target Price of $9.40 According to Brokerages

October 13 at 6:29 AM | americanbankingnews.com

Tvardi Therapeutics (NASDAQ:TVRD) Stock Bumped Down to Strong Sell by Wall Street Zen

October 12 at 1:06 AM | americanbankingnews.com

Tvardi Therapeutics (NASDAQ:TVRD) Stock Bumped Up to "Sell" by Wall Street Zen

October 4, 2026 | americanbankingnews.com

Forumsbeiträge zu Tvardi Therapeutics Inc. Registered shs

September 27, 2026 | finanzen.atF

Tvardi pubblica dati preclinici su inibitore STAT3 per la colite

September 25, 2026 | it.investing.com

New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)

September 25, 2026 | finance.yahoo.com

Tvardi Therapeutics, Inc. Announces Publication Of Preclinical Data Evaluating Its STAT3 Inhibitor In Ulcerative Colitis

September 25, 2026 | marketscreener.comM

New Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC)

September 24, 2026 | globenewswire.com

Tvardi Therapeutics, Inc.(NasdaqCM:TVRD) dropped from S&P Global BMI Index

September 21, 2026 | marketscreener.comM

Tvardi Therapeutics Consensus Price Target Increased by 11.76% to $9.69

September 15, 2026 | msn.com

Tvardi Therapeutics to Participate in Upcoming Investor Events

August 26, 2026 | globenewswire.com

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

August 14, 2026 | globenewswire.com

Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026

August 12, 2026 | globenewswire.com

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109, Plans 2027 Clinical Trial

July 30, 2026 | quiverquant.comQ

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

July 30, 2026 | globenewswire.com

Tvardi Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:TVRD

July 23, 2026 | benzinga.com

Tvardi Therapeutics Inc TVRD

July 14, 2026 | morningstar.comM

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and BridgeBio Pharma (BBIO)

July 10, 2026 | theglobeandmail.com

TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know

July 9, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA, TVRD, BFRI, and KPTI Company Descriptions

Biofrontera NASDAQ:BFRI

$0.84 -0.05 (-5.74%)

As of 02:27 PM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Karyopharm Therapeutics NASDAQ:KPTI

$0.34 -0.09 (-20.68%)

As of 02:29 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Heatwurx NASDAQ:PCSA

$1.68 -0.09 (-4.80%)

As of 02:27 PM Eastern

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Tvardi Therapeutics NASDAQ:TVRD

$1.01 -0.03 (-3.08%)

As of 02:27 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PCSA, TVRD, BFRI, and KPTI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PCSA, TVRD, BFRI, and KPTI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PCSA, TVRD, BFRI, and KPTI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA, TVRD, BFRI, and KPTI Company Descriptions

Biofrontera NASDAQ:BFRI

Karyopharm Therapeutics NASDAQ:KPTI

Heatwurx NASDAQ:PCSA

Tvardi Therapeutics NASDAQ:TVRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PCSA, TVRD, BFRI, and KPTI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PCSA, TVRD, BFRI, and KPTI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PCSA, TVRD, BFRI, and KPTI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA, TVRD, BFRI, and KPTI Company Descriptions

Biofrontera NASDAQ:BFRI

Karyopharm Therapeutics NASDAQ:KPTI

Heatwurx NASDAQ:PCSA

Tvardi Therapeutics NASDAQ:TVRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools